SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...

Invitae is scaling up counseling services after recently signing a contract with Cigna to bring its tests in-network, completing the company’s collection of major ...

Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price ...

The FDA authorized marketing of the first DNA test to help detect hundreds of genetic variants associated with cancer predisposition. The Invitae Common Hereditary Cancers Panel tests DNA in a blood ...

Just two weeks after filing for a $100 million initial public offering, ArcherDx agreed to be acquired by Invitae for up-to-approximately $1.4 billion, in a deal the companies said would create a ...